Barclays PLC Vertex Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Call Options

23 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 15, 2024
SELL
$460.0 - $505.78 $9.94 Million - $10.9 Million
-21,600 Reduced 57.45%
16,000 $7.44 Million
Q2 2024

Aug 14, 2024
BUY
$392.81 - $485.53 $13.5 Million - $16.7 Million
34,300 Added 1039.39%
37,600 $17.6 Million
Q1 2024

May 15, 2024
BUY
$407.69 - $446.08 $856,149 - $936,768
2,100 Added 175.0%
3,300 $1.38 Million
Q4 2023

Feb 15, 2024
BUY
$343.0 - $410.68 $68,600 - $82,136
200 Added 20.0%
1,200 $488,000
Q3 2023

Nov 07, 2023
BUY
$338.18 - $362.46 $338,180 - $362,460
1,000 New
1,000 $348,000
Q4 2022

Feb 13, 2023
BUY
$285.76 - $321.48 $5.14 Million - $5.79 Million
18,000 Added 84.91%
39,200 $11.3 Million
Q1 2022

May 16, 2022
SELL
$221.42 - $260.97 $13.1 Million - $15.4 Million
-59,200 Reduced 73.63%
21,200 $5.53 Million
Q4 2021

Feb 14, 2022
SELL
$177.01 - $223.45 $5.26 Million - $6.64 Million
-29,700 Reduced 26.98%
80,400 $17.7 Million
Q2 2021

Aug 13, 2021
BUY
$187.49 - $221.1 $9.09 Million - $10.7 Million
48,500 Added 78.73%
110,100 $22.2 Million
Q1 2021

May 13, 2021
BUY
$207.02 - $241.31 $9.46 Million - $11 Million
45,700 Added 287.42%
61,600 $13.2 Million
Q4 2020

Feb 11, 2021
BUY
$207.01 - $276.09 $2.4 Million - $3.2 Million
11,600 Added 269.77%
15,900 $3.76 Million
Q2 2020

Aug 12, 2020
SELL
$225.48 - $295.8 $5.16 Million - $6.77 Million
-22,900 Reduced 84.19%
4,300 $1.25 Million
Q1 2020

May 13, 2020
SELL
$199.77 - $247.81 $14.6 Million - $18.1 Million
-73,200 Reduced 72.91%
27,200 $6.47 Million
Q4 2019

Feb 10, 2020
SELL
$166.71 - $223.91 $750,195 - $1.01 Million
-4,500 Reduced 4.29%
100,400 $22 Million
Q3 2019

Nov 14, 2019
SELL
$166.23 - $187.09 $398,952 - $449,016
-2,400 Reduced 2.24%
104,900 $17.8 Million
Q2 2019

Aug 14, 2019
SELL
$164.61 - $190.37 $1.38 Million - $1.6 Million
-8,400 Reduced 7.26%
107,300 $19.7 Million
Q1 2019

May 15, 2019
BUY
$163.73 - $194.7 $16.9 Million - $20.1 Million
103,100 Added 818.25%
115,700 $21.3 Million
Q4 2018

Feb 14, 2019
SELL
$151.91 - $192.21 $20.2 Million - $25.5 Million
-132,900 Reduced 91.34%
12,600 $2.09 Million
Q3 2018

Nov 14, 2018
BUY
$167.73 - $192.74 $3.76 Million - $4.32 Million
22,400 Added 18.2%
145,500 $28 Million
Q2 2018

Aug 14, 2018
BUY
$145.72 - $169.96 $13.2 Million - $15.4 Million
90,600 Added 278.77%
123,100 $20.9 Million
Q1 2018

May 15, 2018
SELL
$151.6 - $177.13 $40.2 Million - $47 Million
-265,500 Reduced 89.09%
32,500 $5.3 Million
Q4 2017

Feb 14, 2018
BUY
$137.28 - $155.55 $9.25 Million - $10.5 Million
67,400 Added 29.23%
298,000 $44.7 Million
Q3 2017

Nov 14, 2017
BUY
$148.13 - $162.24 $34.2 Million - $37.4 Million
230,600
230,600 $35.1 Million

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
221M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email